Daniel Bradbury, a director of Castle Biosciences Inc . (NASDAQ: ), reported selling shares in the company worth $229,225, according to its most recent SEC filing. The transactions took place on January 6, 2025, with shares trading at prices ranging from $28.39 to $29.82. The stock has shown remarkable momentum, having gained more than 20% in the past week and nearly 80% in the past six months, according to InvestingPro data.

The sale, which was executed under a Rule 10b5-1 trading plan, included several transactions. Bradbury sold 1,530 shares at $28.39, 434 shares at the same price, and 3,015 shares at $29.41, among others. Following these transactions, Bradbury held shares through various trusts and an LLC, whose ownership remained indirect. InvestingPro The analysis shows that the company maintains a strong financial position with a current ratio of 7.78, which suggests strong liquidity.

The filing highlights Bradbury’s continued involvement with Castle Biosciences, a company specializing in medical laboratory services. Based on InvestingProAnalyzing Fair Value, the stock appears overvalued at current levels, trading at a P/E ratio of 146.5x. Investors often monitor such insider transactions for insights into the company’s leadership’s confidence in the company’s prospects.

In other recent news, Castle Biosciences, a precision diagnostics company, has made significant strides in the medical diagnostics industry. The company saw a 39% increase in revenue in the third quarter, reaching $85.8 million, primarily due to increased test volume and higher selling prices for the DecisionDx-SCC test. This strong performance led to an upward revision of its full-year revenue guidance to between $320 million and $330 million.

The company also received approval from the New York State Department of Health for the TissueCypher Barrett’s Esophagus test, an important milestone. This AI-driven precision medicine test is designed to predict an individual’s risk of progressing from Barrett’s esophagus to esophageal cancer.

Analyst firms Canaccord Genuity, BTIG, KeyBanc, and Baird responded positively to these developments, adjusting their price targets for Castle Biosciences upward. Canaccord Genuity reiterated a Buy rating and set a $42.00 price target, BTIG raised their price target on the stock to $45.00, KeyBanc raised their price target to $36, and Baird raised its price target to $39.00.

In addition to these developments, Castle Biosciences plans to launch a test for atopic dermatitis by the end of 2025. This test shows the potential to identify patients who are likely to respond to excellent targets. therapy, potentially leading to a reduction in the use of health resources. These recent developments underscore Castle Biosciences’ strong financial performance and confident growth trajectory.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.